Prestige BioPharma Limited

KSE 950210.KS

Prestige BioPharma Limited Market Capitalization on January 14, 2025: USD 617.65 M

Prestige BioPharma Limited Market Capitalization is USD 617.65 M on January 14, 2025, a 51.92% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

Prestige BioPharma Limited 52-week high Market Capitalization is USD 854.30 M on October 30, 2024, which is 38.31% above the current Market Capitalization.
Prestige BioPharma Limited 52-week low Market Capitalization is USD 332.17 M on May 24, 2024, which is -46.22% below the current Market Capitalization.
Prestige BioPharma Limited average Market Capitalization for the last 52 weeks is USD 499.86 M.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

KSE: 950210.KS

Prestige BioPharma Limited

CEO	Ms. So-Yeon Park
IPO Date	Feb. 9, 2021
Location	Singapore
Headquarters	21 Biopolis Road
Employees	66
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Prestige BioPharma Limited, a biopharmaceutical company, engages in the research, development, and marketing of biosimilars and new antibody therapeutics in the Asia Pacific. The company primarily engages in the development of new and similar antibody drugs for solid tumor, pancreatic cancer, breast cancer, gastric cancer, and arthritis. It is also developing vaccines for COVID-19 virus. The company was incorporated in 2015 and is headquartered in Singapore.

Key trends

Past 5 years